Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "EPS"

550 News Found

Zydus Cadila receives tentative USFDA approval for Brivaracetam
News | June 15, 2021

Zydus Cadila receives tentative USFDA approval for Brivaracetam

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad


Alkem launches Perampil tablets at affordable prices
News | June 11, 2021

Alkem launches Perampil tablets at affordable prices

The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access


Lasa Supergenerics FY21 profit up 521%
News | June 02, 2021

Lasa Supergenerics FY21 profit up 521%

Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%


Unilever to launch recyclable tubes for oral care in India
Packaging | June 01, 2021

Unilever to launch recyclable tubes for oral care in India

EPL will supply APR approved 100% recyclable and fully sustainable Platina Tubes for the toothpaste category of Unilever


Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
News | May 31, 2021

Multiple catalysts ahead for Cadila Healthcare: HDFC Securities

Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.


Glenmark Q4 FY 2020-21 revenue grows 3.3%; Net profit up 6.2%
News | May 29, 2021

Glenmark Q4 FY 2020-21 revenue grows 3.3%; Net profit up 6.2%

For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period


Astrazeneca Pharma India Q4FY21 net profit up at Rs 27.27 Cr
News | May 25, 2021

Astrazeneca Pharma India Q4FY21 net profit up at Rs 27.27 Cr

The company has reported total income of Rs.826.40 crores for FY 2020-21


Cadila Healthcare divests animal health business: ICICI Securities
News | May 16, 2021

Cadila Healthcare divests animal health business: ICICI Securities

The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.


Dr. Reddy's Laboratories see marginal dip in FY 2021 PAT
News | May 15, 2021

Dr. Reddy's Laboratories see marginal dip in FY 2021 PAT

Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021


Zydus Wellness reports Rs. 133.13 Cr consolidated PAT in Q4FY21
News | May 10, 2021

Zydus Wellness reports Rs. 133.13 Cr consolidated PAT in Q4FY21

Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.